ClinicalTrials.gg
RecruitingNCT07823205Updated Oct 30, 2026

A Study to Evaluate Different Oral Formulations of KT-621

A Phase 1 interventional study of KT-621 and KT-621 in Healthy Participants, sponsored by Kymera Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Kymera Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • STAT6
  • STAT6 degrader
  • targeted protein degrader
03

In context

Lead sponsor

Kymera Therapeutics, Inc. is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a weight of at least 50 kilograms (kg) if male or 40 kg if female, and a (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening.
  • Participants must be willing and able to read, understand, and sign an form (ICF) which includes compliance with requirements and restrictions listed in the ICF and in this protocol.
  • Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders.
  • Participants who have a clinically relevant surgical history (for example, surgery of the GI tract that could interfere with the PK of the study medication). Note: prior appendectomy or cholecystectomy is not exclusionary.
  • Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  • Participants who have acute GI symptoms at the time of Screening or admission to the CRU (for example, nausea, vomiting, diarrhea, heartburn).
  • Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening or on admission to the CRU.
  • Participants who have been dosed with any drug or device in a clinical study within 30 days or 5 half-lives, or time determined by local requirements (whichever is longer) prior to admission to the CRU.
  • Male participants who do not agree to refrain from sperm donation from admission to the CRU to 90 days after the last dose of KT-621.
  • Male participants (and their partners of ) and female participants who do not agree to the requirements as specified in the clinical protocol.
  • Female participants who are pregnant, lactating, or breastfeeding, or plan to become pregnant during study participation or within 30 days of the last dose of KT-621.
  • Female participants with a positive or undetermined pregnancy result at the Screening visit or at admission to the CRU.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Part A: KT-621 Test Formulation #1

    Participants will receive KT-621 in different oral formulations in a one-way crossover design.

    Drug: KT-621

  • Experimental
    Part B: KT-621 Test Formulation #2

    Participants will receive KT-621 in different oral formulations in a one-way crossover design.

    Drug: KT-621

Interventions

  • DrugKT-621

    KT-621 Reference Oral Formulation

  • DrugKT-621

    KT-621 Test Oral Formulation #1

  • DrugKT-621

    KT-621 Test Oral Formulation #2

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of KT-621

    Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of KT-621

    Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)

  3. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC∞) of KT-621

    Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)

Secondary outcomes

  1. Incidence of adverse events

    Time frame: From signing of the ICF through the safety follow-up on Day 33 (Part A) or Day 39 (Part B)

  2. Incidence of serious adverse events

    Time frame: From signing of the ICF through the safety follow-up visit on Day 33 (Part A) or Day 39 (Part B)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 16, 2026
StartActual
Oct 5, 2026
Primary completionEst.
Apr 2027
CompletionEst.
May 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07823205
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 16, 2026
Start date
Oct 5, 2026
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Kymera Medical Director
Contact
clinicaltrials@kymeratx.com
857-285-5300

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion